Topical Ganciclovir in Patients Receiving Penetrating Keratoplasty With Cytomegalovirus Endotheliitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01359995|
Recruitment Status : Unknown
Verified May 2011 by National Taiwan University Hospital.
Recruitment status was: Recruiting
First Posted : May 25, 2011
Last Update Posted : May 25, 2011
|Condition or disease|
In this study, we recruit 7 immunocompetent patients with unexplained graft failures, which mimicked herpetic anterior uveitis and graft rejection initially, were diagnosed as CMV endotheliitis after aqueous tapping for CMV polymerase chain reaction (PCR). Topical ganciclovir was used to control and prevent the reactivation of CMV without systemic application and their clinical courses were presented after this treatment modality.
The purpose of this study was to evaluate the outcomes of topical ganciclovir in patients with cytomegalovirus endotheliitis receiving penetrating keratoplasty at National Taiwan University hospital.
|Study Type :||Observational|
|Estimated Enrollment :||7 participants|
|Official Title:||Topical Ganciclovir in Patients Receiving Penetrating Keratoplasty With Cytomegalovirus Endotheliitis|
|Study Start Date :||November 2010|
|Estimated Primary Completion Date :||November 2011|
|Estimated Study Completion Date :||November 2011|
- clinical courses before and after topical ganciclovir in patients with CMV endotheliitis [ Time Frame: participants will be monitored after receiving topical ganciclovir,an expected average of 1 year ]evaluations including aqueous PCR for CMV, endothelium cell density on confocal microscopy,degree of anterior chamber inflammation..
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01359995
|Contact: I-Jong Wang, M.D. PhD||886-23123456 ext email@example.com|
|National Taiwan University Hospital||Recruiting|
|Taipei, Taiwan, 100|
|Contact: I-Jong Wang, M.D. PhD 886-23123456 ext 65729 firstname.lastname@example.org|
|Principal Investigator: I-Jong Wang, M.D. PhD|
|Principal Investigator:||I-Jong Wang, M.D. PhD||National Taiwan University Hospital|